Pharmacogenomics and lung transplantation: clinical implications.
Burckart
G J
GJ
Department of Pharmacy, University of Southern California, Los Angeles, CA 90033, USA. burckart@usc.edu
Hutchinson
I V
IV
Zeevi
A
A
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000465:Algorithms; D001682:Biological Availability; D015415:Biomarkers / Q000097:blood; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism; D016903:Drug Monitoring; D004351:Drug Resistance; D020869:Gene Expression Profiling; D006084:Graft Rejection / Q000097:blood / Q000235:genetics* / Q000378:metabolism / Q000517:prevention & control; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D016040:Lung Transplantation; D027361:Organic Anion Transporters / Q000235:genetics / Q000378:metabolism; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D017410:Practice Guidelines as Topic; D016559:Tacrolimus / Q000009:adverse effects / Q000493:pharmacokinetics; D016896:Treatment Outcome
C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D015415:Biomarkers; D007166:Immunosuppressive Agents; D027361:Organic Anion Transporters; D003577:Cytochrome P-450 Enzyme System; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D016559:Tacrolimus